Should Emergency Medicine Physicians Screen for Psychiatric Disorders?
October 1st 2006Emergency department (ED) visits have increased from 89 million in 1992 to more than 110 million in 2002, while the number of EDs decreased by about 15% during the same period. One suspected consequence of ED overcrowding is an increased tendency to disregard a psychiatric problem, especially if it is not the chief complaint.
The Camelford Hysteria: A Lesson for ECT?
October 1st 2006Complaints of persistent memory loss in otherwise well-functioning individuals after recovery from a psychiatric illness through electroconvulsive therapy (ECT) are best viewed as a conversion reaction or a somatoform disorder. The Camelford experience is a model for the complaints of ECT's profound personal memory losses.
Combining Drug Therapy and Psychotherapy for Depression
October 1st 2006It was just over a generation ago that the routine combination of psychotherapy and drug therapy seemed impossible. Then, one meta-analysis found that combined treatment with psychotherapy and medication was found to be notably superior to either treatment alone.
Alternative Brief Interventions for Mild Depression
October 1st 2006Depression has long been recognized as a primary concern for health care providers. Many approaches to treating depression have been developed, ranging from medications, to long-term psychotherapy, to shorter, more structured cognitive-behavioral treatments--all of which help some of the patients, some of the time, to some extent.
Causes, Diagnosis, and Prognosis of ICH, Part I
September 2nd 2006Spontaneous nontraumatic intracerebral hemorrhage is associated with greater mortality and more severe neurologic deficits than any other stroke subtype, with as many as half of all patients dying within 30 days and only 10% of survivors regaining functional independence.
Implications of the Stem Cell Veto on Science in the US
September 1st 2006President George W. Bush's recent veto of the bill to expand federal support for embryonic stem cell research will probably not have any long-term devastating effects on the future treatment of Parkinson disease (PD) or Alzheimer disease (AD).
Troubleshooting Mitoxantrone Use in MS: Combo Therapy May Be Way to Go
September 1st 2006The addition of mitoxantrone (Novantrone) to interferon beta-1b (IFN beta-1b, Betaseron) therapy for the treatment of patients with aggressive multiple sclerosis (MS) unresponsive to standard therapy may reduce the number of new enhancing lesions as well as life-threatening risks associated with mitoxantrone therapy.
Ampakines May Reverse Age-Related Memory Loss
September 1st 2006Ampakines, agents that have been shown to enhance memory, appear to trigger endogenous brain-derived neurotrophic factor (BDNF), a natural mechanism in the brain that could restore neuronal viability and synaptic plasticity through increased trophic support.
ChEIs for the AD Continuum: Redefining Treatment Criteria
September 1st 2006Although cholinesterase inhibitors (ChEIs), specifically donepezil (Aricept), galantamine (Reminyl), and rivastigmine (Exelon), are considered first-line treatment for Alzheimer disease (AD), they are not FDA-approved for use in late-stage disease.
How Does Your Practice Compare? A How-To Guide to Practice Benchmarking
September 1st 2006Everyone is talking about the decline in reimbursements and the increase in overhead costs. While most practices are faltering, some are quite successful--that is, they are economically thriving. So what makes the difference?
New Legislative Move in Battle With Psychologists
September 1st 2006Having lost a few battles over state laws allowing psychologists to prescribe drugs in some cases, organized psychiatry is trying a new tactic--this time at the national level--in order to define professional boundaries in scientifically appropriate ways.